Immuneonco Biopharmaceuticals (shanghai) Inc.
Clinical trials sponsored by Immuneonco Biopharmaceuticals (shanghai) Inc., explained in plain language.
-
New injection aims to stabilize dangerous artery plaques
Disease control Recruiting nowThis early-stage study tests an injectable drug called IMC-001 in 18 people who recently had a heart attack or unstable angina. The goal is to see if it can make fatty plaques in the arteries more stable and less likely to cause future heart problems. Participants receive either …
Phase: EARLY_PHASE1 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 17, 2026 04:54 UTC
-
New hope for rare leukemia: drug duo targets remission and survival
Disease control Recruiting nowThis phase 3 trial tests whether adding IMM01 (timdarpacept) to standard azacitidine helps people with newly diagnosed chronic myelomonocytic leukemia (CMML). About 170 adults will receive either the combo or a placebo plus azacitidine. The main goals are complete remission and o…
Phase: PHASE3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New drug IMC-003 put to the test in healthy women – no cure expected
Knowledge-focused Recruiting nowThis early-stage study tests the safety and tolerability of a new drug called IMC-003 in healthy postmenopausal women aged 45 to 75. Participants receive either the drug or a placebo, and researchers monitor for side effects and how the drug moves through the body. The goal is to…
Phase: PHASE1 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:07 UTC